Yahoo · Sep 14, 2026
Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?
PGEN's Papzimeos is driving strong early sales, while European expansion and pipeline progress could shape the stock's growth outlook.
IN
NASDAQ · INO
Inovio Pharmaceuticals, Inc.
Healthcare · Biotechnology
$1.18
Down-$0.03 (-2.48%)
Updated Sep 26, 2026, 7:37 AM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 114.68M
- P/E ratio
- -0
- Dividend yield
- 0.00%
- 52-week range
- $0.56 – $2.72
- Volume
- 2.25M
- Avg. volume
- 1.16M
Price performance
INO price history
1M range · 20 trading sessions · Daily adjusted prices
INO closed at $1.18 after 20 trading sessions, down 8.53% for the selected period.
- Last close
- $1.18
- Period change
- -8.53%
- Period low
- $1.15
- Period high
- $1.43
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 25, 2026 | $1.22 | $1.23 | $1.17 | $1.18 | 2.25M |
| Sep 24, 2026 | $1.26 | $1.26 | $1.18 | $1.21 | 2.85M |
| Sep 23, 2026 | $1.30 | $1.3076 | $1.24 | $1.25 | 3.03M |
| Sep 22, 2026 | $1.25 | $1.335 | $1.25 | $1.29 | 2.93M |
| Sep 21, 2026 | $1.24 | $1.28 | $1.215 | $1.24 | 2.72M |
| Sep 18, 2026 | $1.215 | $1.27 | $1.21 | $1.24 | 2.91M |
| Sep 17, 2026 | $1.15 | $1.25 | $1.15 | $1.21 | 2.72M |
| Sep 16, 2026 | $1.175 | $1.18 | $1.08 | $1.15 | 3.38M |
| Sep 15, 2026 | $1.20 | $1.2001 | $1.14 | $1.16 | 2.65M |
| Sep 14, 2026 | $1.24 | $1.26 | $1.16 | $1.18 | 3.28M |
| Sep 11, 2026 | $1.30 | $1.31 | $1.23 | $1.25 | 2.39M |
| Sep 10, 2026 | $1.34 | $1.34 | $1.28 | $1.28 | 1.96M |
| Sep 9, 2026 | $1.41 | $1.45 | $1.32 | $1.32 | 2.69M |
| Sep 8, 2026 | $1.43 | $1.45 | $1.38 | $1.42 | 3.47M |
| Sep 4, 2026 | $1.35 | $1.43 | $1.35 | $1.43 | 2.91M |
| Sep 3, 2026 | $1.37 | $1.44 | $1.325 | $1.36 | 4.2M |
| Sep 2, 2026 | $1.34 | $1.42 | $1.29 | $1.36 | 4.43M |
| Sep 1, 2026 | $1.26 | $1.34 | $1.22 | $1.33 | 2.63M |
| Aug 31, 2026 | $1.30 | $1.37 | $1.26 | $1.27 | 5.63M |
| Aug 28, 2026 | $1.27 | $1.32 | $1.255 | $1.29 | 1.7M |
Latest INO news
The latest Smart Investors Daily articles mentioning INO.
Stock researchCompany · Overview
INO research
Overview
Company profile and research snapshot.
Company profile
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $6.00
- Implied upside
- —
- Analysts
- 10
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | Jefferies | Buy | — |
| Aug 3, 2026 | Piper Sandler | Overweight | — |
| Jun 1, 2026 | HC Wainwright & Co. | Neutral | — |
| Nov 14, 2025 | Piper Sandler | Overweight | — |
| Aug 14, 2025 | HC Wainwright & Co. | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 11, 2026
Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms
Inovio Pharmaceuticals (NASDAQ:INO) said its biologics license application for INO-3107, an investigational DNA medicine for recurrent respiratory papillomatosis, or RRP, remains under U.S. Food and Drug Administration review, with a target action date of Oct. 30. President and CEO Jacqueline Shea
SeekingAlpha · Sep 11, 2026
Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript
Inovio Pharmaceuticals, Inc. (INO) H.C.
Yahoo · Sep 10, 2026
Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?
Papzimeos is fueling Precigen's growth, with sales more than doubling sequentially in Q2 and demand continuing to rise in 2026.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
